Thus, we compared TP53 RNA expression level between ETS fusion–positive samples and ETS fusion–negative samples specifically in TP53 wild-type tumors and found TP53 expression level to be significantly higher in ETS fusion–positive prostate cancer (Fig. 4B). This evidence concerns the gene TP53 and prostate carcinoma.